Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind study of bimekizumab in active ankylosing spondylitis
2016-001102-42Phase 2Completed
- Sponsor
- UCB
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimekizumab in ankylosing spondylitis (AS) (4 arms), sponsored by UCB. Primary endpoint: ASAS40 response at Week 12. Started Sep 2016; status: completed.
02
Drugs
bimekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2016-001102-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001102-42.